Stocks Health care IMVT
NASDAQ · Health careImmunovant, Inc. (IMVT)
It posted a net loss of $509M. In fiscal 2026 capital spending exceeded operating cash flow by $407.3M. At September 30, 2026 it held $722.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Immunovant, Inc.
- Net worth
- Immunovant, Inc. has a market value (market cap) of $7.3B at the latest share price, and shareholders' equity of $656.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2026 operations used $407.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Immunovant, Inc.'s next report is expected around February 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Immunovant, Inc. does
Immunovant, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IMVT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | n/a | -$505.6M | -$2.77 | -$407.3M |
| 2025 | n/a | -$413.8M | -$2.73 | -$376.6M |
| 2024 | n/a | -$259.3M | -$1.88 | -$214.6M |
| 2023 | n/a | -$211M | -$1.71 | -$188.4M |
| 2022 | n/a | -$156.7M | -$1.43 | -$106.4M |
| 2020 | n/a | -$107.4M | -$1.22 | -$83.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Immunovant, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 9, 2026
- September 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- July 22, 2026
- July 22, 2026Additional proxy material DEFA14A
- July 22, 2026Proxy statement DEF 14A
Insider trades
What the people running Immunovant, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $922.8K worth of shares in the last 90 days and bought none on the open market. 7% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 28, 2026 | Girao TiagoChief Financial Officer | Sold | 6,606 | $188.3K |
| October 21, 2026 | Stout Jay SChief Technology Officer | Sold | 2,595 | $75.1K |
| October 7, 2026 | Stout Jay SChief Technology Officer | Sold | 2,213 | $70.9K |
| October 7, 2026 | Stout Jay SChief Technology Officer | Sold | 1,596 | $51.2K |
| October 7, 2026 | Gloria MelanieChief Operating Officer | Sold | 2,241 | $71.8K |
| October 7, 2026 | Van Tuyl ChristopherChief Legal Officer | Sold | 1,327 | $42.5K |
| October 2, 2026 | Venker EricChief Executive Officer, Director | Sold | 3,506 | $119.6K |
| October 1, 2026 | Venker EricChief Executive Officer, Director | Exercised options | 92,187 | $1.3M |
Who owns IMVT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 8.4% | November 5, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 226 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 16,186,469 | -761,419 |
| Deep Track Capital, LP | 9,341,151 | -2,185,820 |
| BlackRock, Inc. | 7,180,897 | +606,400 |
| Farallon Capital Management, L.L.C. | 5,805,000 | +4,259,000 |
| Baker Bros. Advisors LP | 5,435,220 | -22,661 |
| State Street Corp | 4,617,005 | +79,076 |
| Morgan Stanley | 4,534,833 | +657,956 |
| TCG Crossover Management, LLC | 4,457,988 | 0 |
| Vanguard Portfolio Management LLC | 3,910,509 | +205,604 |
| Vanguard Capital Management LLC | 3,638,681 | +18,631 |
| Jennison Associates LLC | 3,310,238 | +113,533 |
| Rtw Investments, LP | 3,177,849 | 0 |
| Two Seas Capital LP | 3,148,505 | -53,457 |
| ADAR1 Capital Management, LLC | 2,330,716 | -348,294 |
| Geode Capital Management, LLC | 2,234,602 | +142,500 |
| Woodline Partners LP | 1,975,869 | 0 |
| Goldman Sachs Group Inc | 1,751,183 | -33,924 |
| Armistice Capital, LLC | 1,736,000 | -1,828,916 |
| Alpine Global Management, LLC | 1,375,000 | -1,261,925 |
| Perceptive Advisors LLC | 1,357,383 | -240,000 |
Insiders
11 insiders reported holding 2,492,766 shares in total, about $88.3M at the last price.
| Holder | Shares |
|---|---|
| Torti FrankDirector | 1,009,228 |
| Venker EricChief Executive Officer, Director | 257,075 |
| Girao TiagoChief Financial Officer | 234,192 |
| Gloria MelanieChief Operating Officer | 217,060 |
| Stout Jay SChief Technology Officer | 198,937 |
| Van Tuyl ChristopherChief Legal Officer | 175,218 |
| Hughes Douglas J.Director | 134,653 |
| Pande AtulDirector | 116,731 |
| Fromkin Andrew J.Director | 74,382 |
| Bauer JakeDirector | 38,896 |
Questions about IMVT
What does Immunovant, Inc. do?
Immunovant, Inc. is a company in the Health care sector, listed on NASDAQ as IMVT. Its shares trade on NASDAQ under the ticker IMVT.
What is Immunovant, Inc.'s net worth?
Immunovant, Inc. has a market value (market cap) of $7.3B at the latest share price, and shareholders' equity of $656.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Immunovant, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $509M.
When did Immunovant, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Immunovant, Inc.'s next earnings report?
Immunovant, Inc.'s next report is expected around February 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IMVT with
Follow IMVT
Get an email when Immunovant, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Immunovant, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.